Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2007-07-27
2011-10-11
Hayes, Robert C (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
active
08034347
ABSTRACT:
The present invention provides an isolated protein comprising a pro-domain of a proneurotrophin, methods for producing the protein, and pharmaceutical compositions containing the isolated protein. The invention also provides a nucleic acid molecule which encodes the protein and a vector containing the nucleic acid molecule. The present invention further provides a method for cleaving a proneurotrophin protein to a mature neurotrophin. In addition, the invention relates to methods for inducing apoptosis in a cell of a mammal expressing p75 surface receptors or p75 and trk receptors. The methods include causing the p75 receptor to bind a pharmaceutical composition containing a pro-domain of a proneurotrophin or administering to the mammal an effective amount of a cleavage-resistant proneurotrophin and an inhibitor of trk activation. The invention also relates to a method for inhibiting apoptosis of a cell in a mammal by administering an effective amount of a molecule which inhibits binding of a proneurotrophin to a p75 receptor. Also provided, are kits and methods for screening a human for a condition associated with undesired apoptosis.
REFERENCES:
patent: 5169764 (1992-12-01), Shooter et al.
patent: 5288622 (1994-02-01), Gray et al.
patent: 6077829 (2000-06-01), Tanaka et al.
patent: 6172086 (2001-01-01), Zelle et al.
patent: 7507799 (2009-03-01), Hempstead et al.
patent: WO 97/36607 (1997-10-01), None
patent: WO00/24415 (2000-05-01), None
patent: WO 00/75278 (2000-12-01), None
patent: WO 01/52843 (2001-07-01), None
patent: WO 02/096356 (2002-12-01), None
Botchkarev, et al., “A role for p75 neurotrophin receptor in the control of apoptosis-driven hair follicle regression”,The FASEB Journal2000, 14:1931-1942.
Chao, et al., “Neurotrophins: To Cleave or Not to Cleave”,Neuron2002, 33:9-12.
Chen, et al., “Characterization of nerve growth factor precursor protein expression in rat round spermatids and the trophic effects of nerve growth factor in the maintenance of Sertoli cell viability”,Molecular and Cellular Endocrinology1997, 127:129-136.
Delsite, et al., “Characterization of Nerve Growth Factor Precursor Protein Expression by Human Prostate Stromal Cells: A Role in Selective Neurotrophin Stimulation of Prostate Epithelial Cell Growth”,The Prostate1999, 41:39-48.
Drinkwater, et al., “The Carboxyl Terminus of Nerve Growth Factor is Required for Biological Activity”,The Journal of Biological Chemistry1993, 268(31):23202-23207.
Heymach, Jr., et al., “The Regulated Secretion and Vectorial Targeting of Neurotrophins in Neuroendocrine and Epithelial Cells”,The Journal of Biological Chemistry1996, 271(41):25430-25437.
Heymach, Jr., et al., “The Biosynthesis of Neurotrophin Heterodimers by Transfected Mammalian Cells”,The Journal of Biological Chemistry1995, 270(20):12297-12304.
Kolbeck, et al., “Characterisation of neurotrophin dimers and monomers”,Eur. J. Biochem. 1994, 225:995-1003.
Lee, et al., “Regulation of Cell Survival by Secreted Proneurotrophins”,Science2001, 294:1945-1948.
Mowla, et al., “Biosynthesis and Post-translational Processing of the Precursor to Brain-derived Neurotrophic Factor”,The Journal of Biological Chemistry2001, 276(16):12660-12666.
Rattenholl, et al., “Pro-Sequence Assisted Folding and Disulfide Bond Formation of Human Nerve Growth Factor”,J. Mol. Biol. 2001, 305:523-533.
Seidah, et al., “Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases”,FEBS Letters1996, 379:247-250.
Suter, et al., “NGF/BDNF Chimeric Proteins: Analysis of Neurotrophin Specificity by Homolog-scanning Mutagenesis”,The Journal of Neuroscience1992, 12(1):306-318.
Suter, et al., “Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF”,The EMBO Journal1991, 10(9):2395-2400.
Wang, et al., “p75NTRMediates Neurotrophin-Induced Apoptosis of Vascular Smooth Muscle Cells”,American Journal of Pathology2000, 157(4):1247-1258.
Yardley, et al., “Expression of nerve growth factor mRNA and its translation products in the anagen hair follicle”,Experimental Dermatology2000, 9:283-289.
Akinaga, et al., “Antitum or effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action”,Cancer Chemother Pharmacol1992, 29: 266-272.
Barker, et al., “p75NTR Is Positively Promiscuous: Novel Partners and New Insights”,Neuron2004, 42:529-533.
Brann, et al., “Ceramide Signaling Downstream of the P75 Neurotrophin Receptor Mediates the Effects of Nerve Growth Factor on Outgrowth of Cultured Hippocampal Neurons”,J. Neurosci1999, 19(19):8199-8206.
Evans, et al., “Antitumor Activity of CEP-751 (KT-6587) on Human Neuroblastoma and Medulloblastoma Xenografts”,Clin. Cancer Res. 1999, 5(11):3594-3602.
Fahnestock, et al., “The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease”,Molecular and Cellular Neuroscience2001, 18:210-220.
Fotouhi, et al., “Potent Peptide Inhibitors of Stromelysin Based on the Prodomain Region of Matrix Metalloproteinases”,The Journal of Biological Chemistry1994, 269(48):30227-30231.
Frade, et al., “Induction of cell death by endogenous nerve growth factor through its p75 receptor”,Letters to Nature1996, 383(6596):166-168.
Mizushima, et al., “Antitumor Therapeutic Effect of Neurotropin on Transplanted Tumors in Rats”,Oncology1984, 41:289-292.
Reinshagen, et al., “Commercial mouse and human nerve growth factors contain nerve growth factor prohormone isoforms”,Journal of Neuroscience Methods1997, 76(1):75-81.
Rowinsky, et al., “Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies”,Journal of Clinical Oncology2000, 18(1):178-186.
Cortazzo, MH, et al., “Nerve Growth Factor (NGF)-Mediated Protection of Neural Crest Cells from Antimitotic Agent-Induced Apoptosis: the Role of the Low Affinity NGF Receptor”,The Journal of Neuroscience, vol. 16, No. 2, pp. 3895-3899; Jun. 15, 1996.
Gentry JJ. et al.; “Nerve Growth Factor Activation of Nuclear Factor .kapp.B through Its p75 Receptor Is an Anti-apoptotic Signal in RN22 Schwannoma Cells”,The Journal of Biological Chemistry, vol. 275, No. 11, pp. 7558-7565; Mar. 17, 2000.
Soilu-Haenninen M. et al., “Nerve Growth Factor Signaling Through p75 induces apoptosis in Schwann cells via a Bcl-2-independent pathway”,Journal of Neuroscience, vol. 19, No. 12, pp. 4828-4838; Jun. 15, 1999.
Nykjaer A. et al., “Sortilin is Essential for proNGF-induced Neuronal Cell Death”,Nature, vol. 427, pp. 843-848; Feb. 26, 2004. (Abstract).
Capsoni, S., et al., “Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration”,Proc. Natl. Acad. Sci. USA, vol. 107, pp. 12299-12304 (2010).
Feng, D., et al., “Molecular and Structural Insight into proNGF Engagement of p75NTR and Sortilin”,J. Mol. Biol., 396, pp. 967-984 (2010).
He, X. and Garcia, K.L., “Structure of Nerve Growth Factor Complexed with the Shared Neurotrophin Receptor p75”,Science, vol. 304, pp. 870-875, May 7, 2004.
Frade, J.M. et al., “Control of early cell death by BDNF in the chick retina”,Development, vol. 124, pp. 3313-3320 (1997).
Das, A., et al., “Time-Dependent Increases in Protease Activities for Neuronal Apoptosis in Spinal Cords of Lewis Rats During Development of Acute Experimental Autoimmune Encephalomyelitis”,Journal of Neuroscience Research, vol. 86, pp. 2992-3001 (2008).
Hempstead Barbara L.
Kermani Pouneh
Lee Ramee
Teng Kenneth K.
Cornell Research Foundation Inc.
Hayes Robert C
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Method for inhibiting apoptosis through the p75 neurotrophin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting apoptosis through the p75 neurotrophin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting apoptosis through the p75 neurotrophin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4302527